Secures $50m Exclusive German Supply Agreement with ADREX
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 12 May 2026, 8:22 a.m. |
| Price Sensitive | Yes |
Bioxyne Secures $50m Exclusive German Supply Deal
- Bioxyne enters $50m, 2-year supply agreement with German partner ADREXpharma
- Agreement includes $25m minimum commitment in first 12 months, with automatic renewal
- ADREXpharma granted exclusive rights for Dr Watson® brand in Germany
Bioxyne Limited (ASX: BXN), through its wholly owned subsidiary Breathe Life Sciences (BLS), has entered into a two-year, $50 million supply agreement with German pharmaceutical company ADREXpharma GmbH to supply BLS's GMP-manufactured medicinal cannabis products in Germany. The 24-month contract includes a $25 million minimum commitment in the first 12 months, with automatic renewal for a further 12 months, providing near-term revenue visibility and a defined sales pathway into Europe. Supply will comprise BLS's Australian GMP-manufactured cannabis flower and other products, with volumes underpinned by onward distribution to a network of established customers in Germany. This represents a material expansion on the initial supply agreement executed with Adrex in June 2025 and reflects increasing demand for BLS's GMP-certified products across European markets. Adrex has been granted exclusive rights in Germany to distribute BLS's proprietary Dr Watson® brand, supporting targeted market penetration in one of Europe's largest and most developed medicinal cannabis markets. The expanded agreement aligns with Bioxyne's strategy to scale its GMP-certified manufacturing and supply platform across regulated international markets, with Europe, particularly Germany and the United Kingdom, remaining a key focus for growth, supported by increasing patient demand and evolving regulatory frameworks.
The agreement includes a $25 million minimum commitment in the first 12 months, with automatic renewal for a further 12 months, providing near-term revenue visibility.
The agreement strengthens Bioxyne's position in Germany, Europe's largest medicinal cannabis market, and supports the company's strategy to expand its GMP-certified manufacturing and supply platform across regulated international markets.